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In both men and women, circulating androgen levels decline
with advancing age. Until now, results of several small studies
on the relationship between endogenous androgen levels and
atherosclerosis have been inconsistent.
In the population-based Rotterdam Study, we investigated
the association of levels of dehydroepiandrosterone sulfate
(DHEAS) and total and bioavailable testosterone with aortic
atherosclerosis among 1,032 nonsmoking men and women
aged 55 yr and over. Aortic atherosclerosis was assessed by
radiographic detection of calcified deposits in the abdominal
aorta, which have been shown to reflect intimal atherosclerosis.
Relative to men with levels of total and bioavailable tes-
tosterone in the lowest tertile, men with levels of these hor-
mones in the highest tertile had age-adjusted relative risks of
0.4 [95% confidence interval (CI), 0.2–0.9] and 0.2 (CI, 0.1–0.7),
respectively, for the presence of severe aortic atherosclerosis.
The corresponding relative risks for women were 3.7 (CI, 1.2–
11.6) and 2.3 (CI, 0.7–7.8). Additional adjustment for cardio-
vascular disease risk factors did not materially affect the re-
sults in men, whereas in women the associations diluted. Men
with levels of total and bioavailable testosterone in subse-
quent tertiles were also protected against progression of aor-
tic atherosclerosis measured after 6.5 yr (SD  0.5 yr) of fol-
low-up (P for trend  0.02). No clear association between
levels of DHEAS and presence of severe aortic atherosclerosis
was found, either in men or in women. In men, a protective
effect of higher levels of DHEAS against progression of aortic
atherosclerosis was suggested, but the corresponding test for
trend did not reach statistical significance.
In conclusion, we found an independent inverse association
between levels of testosterone and aortic atherosclerosis in
men. In women, positive associations between levels of tes-
tosterone and aortic atherosclerosis were largely due to ad-
verse cardiovascular disease risk factors. (J Clin Endocrinol
Metab 87: 3632–3639, 2002)
ANDROGEN LEVELS DECLINE with advancing age,both in men (1, 2) and women (3). Although it is not
known whether this decline in hormonal activity is causally
related to physical changes during aging (4), exogenous
androgens are considered to be an attractive treatment mo-
dality to potentially benefit psychological well-being, body
composition, and strength in the elderly (5–7). Dehydroepi-
androsterone (DHEA) is being sold in increasing amounts
over the counter, several androgen replacement therapy mo-
dalities are prescribed for men (5), and its use in women is
likely to become more widespread (8). In animal models,
treatment with testosterone tended to inhibit the develop-
ment of atherosclerosis in male rabbits (9), whereas in female
monkeys it induced exacerbation of atherosclerosis (10), sug-
gesting gender-specific effects of androgens on cardiovas-
cular disease. In humans, the effects of androgen treatment
on cardiovascular disease have not been studied. Endoge-
nous testosterone levels were not found to be related to
cardiovascular events in men (11–14) or women (15),
whereas studies on endogenous levels of DHEA or DHEA
sulfate (DHEAS) and cardiovascular events showed conflict-
ing results (16–18). Results of several studies on endogenous
androgen levels and atherosclerosis have been inconsistent
(19–25). However, most of these studies were relatively small
(19–24).
In the population-based Rotterdam Study, we investigated
the association between levels of endogenous androgens and
aortic atherosclerosis among a gender-stratified sample of
more than 1,000 men and women aged 55 yr and over.
Subjects and Methods
The Rotterdam Study
The Rotterdam Study is a population-based prospective cohort study
designed to assess the occurrence and the determinants of chronic dis-
eases in an aging population (26). The study was approved by the
medical ethics committee of the Erasmus Medical Center (Rotterdam,
The Netherlands). The cohort includes 3,105 men and 4,878 women aged
55 yr and over (78% of the eligible population) living in a defined district
in Rotterdam. Written informed consent was obtained from all partic-
ipants. Baseline data were collected from 1990 until 1993. The third
examination phase took place from 1997 until 1999. Between these ex-
aminations, 1,992 persons died, and 35 were lost to follow-up. Fifty-five
subjects were not invited for the third examination phase because they
moved outside the area, resulting in 5,901 invited subjects. Of the invited
subjects, 1,922 men and 2,875 women (81%) participated.
Endogenous androgens
At the baseline examination of the Rotterdam Study, blood samples
were drawn by venapuncture from nonfasting subjects at the research
center between 0830 and 1600 h. Levels of steroid hormones were mea-
sured in plasma. For the collection of plasma, blood was collected in 5-ml
tubes containing 0.5 ml sodium citrate solution. All tubes were stored
on ice before and after blood sampling. Platelet-free plasma was ob-
tained by two-stage centrifugation, first for 10 min at 1600 g at 4 C and
then for 30 min at 7000 g at 4 C. Platelet-free samples were immediately
frozen in liquid nitrogen and transferred to the laboratory. At the lab-
oratory, plasma samples were stored at 80 C until laboratory studies
Abbreviations: BMI, Body mass index; CI, confidence interval; CT,
computed tomography; DHEAS, dehydroepiandrosterone sulfate;
HDL, high-density lipoprotein; WHR, waist-to-hip ratio.
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were performed. For the purpose of the present study, plasma levels of
DHEAS, testosterone, and SHBG were estimated in 12 separate batches
of samples using coated tube (testosterone) or double antibody RIAs
(DHEAS and SHBG), purchased from Diagnostic Systems Laboratories,
Inc. (Webster, TX). Because of the relatively small volumes of plasma
available, all values reported are single sample estimations. Intra-assay
coefficients of variation, determined on the basis of duplicate results of
internal quality control pools with three different levels of each analyte,
were less than 4% for SHBG, 13% for testosterone, and 15% for DHEAS.
Because interassay variations were relatively large (14% SHBG, 19%
testosterone, and 24% DHEAS), we multiplied all concentrations within
a batch with a factor, which made results for the internal quality control
pools comparable. This reduced interassay variations to 3%, 7%, and
10%, respectively, and was considered justified because the relative
differences in the results for the high and middle internal quality control
pools per batch were comparable, as evidenced by correlations between
these results (r  0.91 for SHBG, r  0.75 for testosterone, and r  0.58
for DHEAS; all P  0.05). Assays were performed blind with respect to
information on the subject. As a measure of bioavailable testosterone,
non-SHBG-bound testosterone was calculated on the basis of hormone,
SHBG, and albumin (see below) levels, and respective affinity constants
according to the method described by So¨dergård et al. (27) and van den
Beld et al. (28).
Aortic atherosclerosis
At baseline and follow-up, lateral radiographic films of the lumbar
spine (T12-S1) were made from a fixed distance while the participant
was seated. Atherosclerosis was diagnosed off-line by detecting calcified
deposits in the abdominal aorta, as described previously (29, 30), by a
technician and scored independently of the subjects’ exposure status (in
the present study, levels of endogenous androgens). Calcification was
considered present when linear densities were present in an area parallel
and anterior to the lumbar spine (L1-L4). Values for the extent of cal-
cification were scored according to the length of the involved area (1
cm, 1–2.5 cm, 2.5–5 cm, 5–10 cm, and 10 cm). We considered the first
two classes as mild, the third class as moderate, and fourth and fifth
classes as severe atherosclerosis.
Progression of aortic atherosclerosis was defined as the occurrence of
new calcifications or enlargement of the calcified area present at base-
line. Baseline and follow-up films were examined in pairs. The extent of
progression was graded (0.5–1 cm, 1–2.5 cm, 2.5–5 cm, and 5 cm), but
because of the relatively small numbers available for analysis, we com-
bined severity grades into two groups: progression absent and progres-
sion present. No subject showed a decrease in extent of aortic calcifi-
cation. All films were read by one observer who was aware of the date
of the radiographs. Before the scoring, a sample of the films was read
by two observers simultaneously so as to reach agreement on the in-
terpretation of the scoring protocol. Previously determined interob-
server agreement on progression scoring (absent vs. present), based on
758 pairs of lateral radiographic films of the lumbar spine at our de-
partment, reached a percentage of agreement of atherosclerotic change
of 88, and a  statistic of 0.74 (29).
The validity of radiographic assessment of aortic atherosclerosis has
been studied by comparing results of this method with data obtained at
autopsy. Radiographic assessment was shown to be highly specific, and
in most cases visible calcification represented advanced intimal athero-
sclerosis (31). Intimal calcification was also shown to be clearly distin-
guishable from medial calcification (32). A comparison study involving
computed tomography (CT) was performed at our department. In 56
unselected elderly persons, aortic calcifications were independently
assessed by radiography and CT. Calcifications were detected on ab-
dominal radiography in 32 subjects. In all but one person, these calci-
fications were shown to be located in the aorta on the corresponding CT
images (30).
Aortic calcification is known to be associated with risk factors for
cardiovascular disease (29, 30) and with atherosclerosis at other sites
(33), and it predicts cardiovascular morbidity and mortality (34, 35).
When aortic calcification (as detected by radiography) was compared
with coronary artery calcium (as detected by electron-beam CT) in 457
participants in the Rotterdam Study, aortic calcification was present in
3.9% of participants in the lowest tertile of coronary artery calcium,
in 13.7% of those in the middle tertile of coronary artery calcium, and
in 31.5% of those in the highest tertile of coronary artery calcium (P for
trend  0.001, adjusted for age and gender).
Other variables
During a home interview at baseline, a trained research assistant
gathered information on current and past health, medication, smoking
habits, and age of menopause (self-reported age of last menstruation).
Participants were subsequently invited to visit the research center,
where intake of alcohol was assessed using a food frequency question-
naire (36). Height, weight, and waist and hip circumferences were mea-
sured while each participant was wearing indoor clothing without
shoes. Body mass index (BMI, weight divided by height squared) and
waist-to-hip ratio (WHR) were computed. Two blood pressure mea-
surements were taken with a random-zero sphygmomanometer after 5
min of rest with the subject in sitting position and averaged. A veni-
puncture was performed, and nonfasting blood samples were obtained.
They were directly put on ice, and serum samples were processed within
30 min, after which they were kept frozen at 20 C. We used an au-
tomated enzymatic procedure to determine serum total cholesterol level
(37). High-density lipoprotein (HDL) cholesterol was measured simi-
larly, after precipitation of the non-HDL cholesterol fraction. Albumin
was measured using a colorimetric method (KONE Diagnostics, Espoo,
Finland). As part of the Rotterdam Study, glucose metabolism was
studied using a nonfasting oral glucose tolerance test. Previous results
from the Rotterdam Study indicate that nonfasting postload insulin
levels are similar to fasting postload levels (38), and it is shown that
postload insulin provides a good measure of insulin resistance in non-
diabetic subjects (39). Therefore, we used postload insulin as a measure
of insulin resistance in nondiabetic subjects. Diabetes mellitus was de-
fined as the use of glucose-lowering medication or a random or postload
serum glucose level of at least 11.1 mmol/liter according to the World
Health Organization criteria (40).
Population for analysis
We determined levels of steroid hormones in plasma in a gender-
stratified random sample of 1432 subjects (667 men and 765 women). In
1252 subjects (610 men and 642 women), data on aortic atherosclerosis
were available. To increase power for the current analyses, we addi-
tionally sampled plasma from 233 subjects (116 men and 117 women)
with moderate to severe aortic atherosclerosis present at baseline. We
excluded participants using systemic corticosteroids (16 men and 26
women) or hormone supplements (1 man and 15 women) at time of
blood drawing. One woman used both types of medication, leaving 1428
subjects (709 men and 719 women). All women were postmenopausal.
To remove residual confounding by current smoking, which influences
levels androgens in men (41, 42) and women (43–45), we additionally
excluded smoking men (n  205) and women (n  191), leaving 1032
subjects for the current analyses (504 men and 528 women). Due to
logistical reasons and insufficient plasma available, data on DHEAS and
total testosterone were missing for 56 men and 44 women, and 76 men
and 58 women, respectively. Due to missing data on binding protein
levels, data on bioavailable testosterone were additionally missing for
121 men and 114 women. The sex and age-specific prevalence of car-
diovascular disease risk factors and aortic atherosclerosis in subjects
with missing data on hormone levels were comparable with the prev-
alence of these risk factors in the 1032 subjects available for the current
analyses.
Statistical analysis
We stratified all analyses by sex to study sex-specific associations.
Tertiles of endogenous androgen levels were computed in the randomly
selected eligible population (i.e. without taking the additionally sampled
cases with moderate to severe aortic atherosclerosis at baseline into
account). Insulin was natural-log transformed to obtain a normal
distribution.
First, we computed age-adjusted levels of cardiovascular disease risk
factors according to tertiles of levels of androgens by using general linear
models. Tests of significance for the coefficients of the ordered variable
of tertiles of androgen levels in subsequent linear regression models with
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the cardiovascular disease risk factor as dependent variable were con-
sidered to be tests for trend.
Second, we used logistic regression models to compute age and
multivariate-adjusted odds ratios for severe aortic atherosclerosis ac-
cording to tertiles of levels of androgens. Odds ratios as retrieved from
these logistic analyses are referred to as relative risks. In these analyses,
the number of participants with severe aortic atherosclerosis in subse-
quent tertiles of androgen levels was compared with the number of
participants without any aortic atherosclerosis in these tertiles. Analyses
were initially adjusted for age by entering age as a continuous variable
in the model. In subsequent models, we additionally adjusted for BMI,
systolic blood pressure, cholesterol level, HDL cholesterol level, pres-
ence of diabetes mellitus (yes or no), smoking (ever or never), and
alcohol intake (in four categories: nondrinking, less than one glass, one
to two glasses, and more than two glasses per day). After exclusion of
diabetic subjects, we additionally adjusted the analyses for insulin. In
analyses regarding women, we additionally adjusted for years since
menopause and ever-use of hormone replacement therapy (yes or no).
Third, we used logistic regression models to compute age and mul-
tivariate-adjusted odds ratios for progression of aortic atherosclerosis
during follow-up according to tertiles of androgen level at baseline.
These analyses were additionally adjusted for duration of follow-up.
In all multivariate-adjusted models, we used missing value indicators
for missing data on categorical covariates (46), whereas for missing data
on continuous covariates we imputed the gender-specific mean value of
the respective variable as calculated from the study population of 1032
subjects.
We considered two-sided P values less than 0.05 to be statistically
significant. SPSS 10.0 for Windows (SPSS, Inc., Chicago, IL) was used for
all analyses.
Results
The baseline characteristics of the study population are
shown in Table 1. The age of participating men ranged from
55.0–89.4 yr, with a mean of 67.9 yr. In women, age ranged
from 55.1–89.0 yr, with a mean of 69.5 yr. Aortic atheroscle-
rosis was absent in 175 men (35%) and 188 women (36%),
whereas severe atherosclerosis was present in 47 men and 46
women (9% in both sexes).
Table 2, A and B, shows the age-adjusted levels of car-
diovascular disease risk factors according to tertiles of levels
of endogenous androgens. In men, higher measures of body
weight were associated with lower levels of DHEAS and
testosterone, and former smokers were overrepresented in
the lower tertiles of levels of testosterone (Table 2A). Higher
blood pressure levels tended to be associated with lower
levels of testosterone, although tests for trend did not reach
statistical significance. In nondiabetic men, levels of postload
insulin were inversely associated with levels of testosterone.
In women, higher body weight, BMI, and waist circumfer-
ence, and lower levels of HDL cholesterol were associated
with higher levels of testosterone (Table 2B). In nondiabetic
women, levels of postload insulin tended to be positively
associated with levels of DHEAS and testosterone, whereas
diabetes mellitus tended to be more prevalent in women with
lower levels of DHEAS and higher levels of testosterone.
TABLE 1. Baseline characteristics of the study sample
Characteristic Mena (n  504) Womenb (n  528)
Age (yr) 67.9  7.3 69.5  7.9
Weight (kg) 79.4  9.9 69.5  10.6
BMI (kg/m2) 26.1  2.9 26.7  3.7
Waist circumference (cm) 94.7  9.4 87.6  10.8
WHR (cm/cm) 0.96  0.07 0.87  0.09
Systolic blood pressure (mm Hg) 138.2  20.3 139.5  21.2
Diastolic blood pressure (mm Hg) 74.8  10.7 72.8  11.0
Total cholesterol (mmol/liter) 6.4  1.1 7.0  1.3
HDL cholesterol (mmol/liter) 1.2  0.4 1.5  0.4
Postload insulin (mU/liter)c 43.2 (40.1; 46.5) 49.6 (46.2; 53.3)
Time since menopause (yr) 20.5  9.1
Albumin (g/liter) 43.4  2.6 43.1  2.5
SHBG (nmol/liter) 34.7  14.0 43.8  17.8
DHEAS (mol/liter) 4.2  2.5 2.6  2.0
Total testosterone (nmol/liter) 11.2  3.9 1.4  0.8
Bioavailable testosterone (nmol/liter) 6.8  2.9 0.7  0.4
Diabetes mellitus (%) 8 8
Former smokers (%) 88 34
Alcohol drinkers (%)d 91 74
Ever-use of hormone replacement therapy (%) 14
Aortic atherosclerosis (%)
Mild 32 30
Moderate 24 26
Severe 9 9
Data represent mean  SD or percentages.
a For some men, data were missing on weight and BMI (n 1), waist circumference and WHR (n 31), blood pressure (n 5), HDL cholesterol
(n  2), albumin (n  126), SHBG (n  83), DHEAS (n  56), testosterone (n  76), bioavailable testosterone (n  197), diabetes mellitus (n 
14), and alcohol drinking (n  50).
b For some women, data were missing on BMI (n  1), waist circumference (n  39), WHR (n  40), blood pressure (n  2), total cholesterol
(n  1), HDL cholesterol (n  3), albumin (n  113), time since menopause (n  12), SHBG (n  65), DHEAS (n  44), testosterone (n  58),
bioavailable testosterone (n 172), diabetes mellitus (n 24), alcohol drinking (n 62), and ever-use of hormone replacement therapy (n 12).
c Postload insulin was used as a measure of insulin resistance in nondiabetic subjects only [n  409 men (excluded are men with diabetes
mellitus, n 41; missing data on diabetes mellitus, n 14; and men in whom insulin levels were missing, n 40), and n 420 women (excluded
are women with diabetes mellitus, n  42; missing data on diabetes mellitus, n  24; and women in whom insulin levels were missing, n 
42)]. Because insulin was skewed, geometric mean values and 95% CI values in parentheses are shown.
d 1 glass; 1–2 glasses; and 2 glasses per day.
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In Table 3, A and B, the relative risks for severe aortic
atherosclerosis according to tertiles of levels of androgens are
shown. Levels of DHEAS were not associated with the pres-
ence of severe aortic atherosclerosis in men or women (Table
3, A and B). Men with levels of testosterone in the second and
third tertile had lower risks of severe aortic atherosclerosis.
Multivariate adjustment did not materially change the re-
sults (Table 3A). Women with levels of testosterone in the
second and third tertile tended to have higher risks of pres-
ence of severe aortic atherosclerosis. Multivariate adjustment
diluted the associations (Table 3B). Additional adjustment
for waist circumference, or adjustment for waist circumfer-
ence instead of BMI, did not materially change the results in
either men or women, nor did additional adjustment for
postload insulin after exclusion of diabetic subjects (data not
shown). Exclusion of male or female participants using se-
rum lipid-lowering or antihypertensive medication did not
affect the results either (data not shown).
Of the men with complete data on DHEAS, total testos-
terone, and bioavailable testosterone, 82% participated in the
third examination phase, and in 287, 282, and 208 of these
men, respectively, follow-up information of aortic athero-
sclerosis was available. Of the women with complete data on
DHEAS, total testosterone, and bioavailable testosterone,
81% participated in the third examination phase, and in 272,
263, and 197 of these women, respectively, follow-up infor-
TABLE 3A. Relative risk (RR) for severe aortic atherosclerosisa according to tertiles of levels of endogenous androgens in
nonsmoking men
Aortic atherosclerosis
RR (95% CI)b RR (95% CI)c
Severe (n) None (n)
DHEAS tertiles
0.1 and 2.6 mol/liter 15 42 1 (ref) 1 (ref)
2.6 and 4.6 mol/liter 16 56 1.0 (0.4; 2.3) 0.9 (0.4; 2.2)
4.6 and 15.9 mol/liter 13 58 0.8 (0.3; 2.0)
P trend  0.68
0.9 (0.3; 2.2)
P trend  0.71
Total T tertiles
0 and 9.8 nmol/liter 19 38 1 (ref) 1 (ref)
9.8 and 12.6 nmol/liter 14 48 0.7 (0.3; 1.5) 0.7 (0.3; 1.6)
12.6 and 36.8 nmol/liter 9 60 0.4 (0.2; 0.9)
P trend  0.03
0.4 (0.1; 1.0)
P trend  0.04
Bioavailable T tertiles
0 and 5.6 nmol/liter 16 24 1 (ref) 1 (ref)
5.6 and 7.5 nmol/liter 8 36 0.4 (0.1; 1.0) 0.3 (0.1; 0.9)
7.5 and 28.7 nmol/liter 5 43 0.2 (0.1; 0.7)
P trend  0.006
0.2 (0.0; 0.6)
P trend  0.004
T, Testosterone; ref, reference category (lowest tertile of endogenous androgen).
a No. of men with severe aortic atherosclerosis compared with number of men without aortic atherosclerosis.
b RR as retrieved from logistic regression analysis, adjusted for age.
c RR as retrieved from logistic regression analysis, adjusted for age, BMI, systolic blood pressure, cholesterol level, HDL cholesterol level,
diabetes mellitus (yes/no), smoking (ever/never), and alcohol intake (4 categories).
TABLE 3B. Relative risk (RR) for severe aortic atherosclerosisa according to tertiles of levels of endogenous androgens in nonsmoking
women
Aortic atherosclerosis
RR (95% CI)b RR (95% CI)c
Severe (n) None (n)
DHEAS tertiles
0.1 and 1.5 mol/liter 16 42 1 (ref) 1 (ref)
1.5 and 2.9 mol/liter 13 61 0.6 (0.3; 1.6) 0.5 (0.2; 1.5)
2.9 and 13.6 mol/liter 11 67 0.9 (0.3; 2.3)
P trend  0.70
0.7 (0.2; 2.2)
P trend  0.33
Total T tertiles
0 and 1.0 nmol/liter 5 57 1 (ref) 1 (ref)
1.0 and 1.6 nmol/liter 18 57 3.0 (0.9; 9.4) 4.4 (1.1; 17.5)
1.6 and 6.9 nmol/liter 20 54 3.7 (1.2; 11.6)
P trend  0.03
2.8 (0.7; 11.5)
P trend  0.19
Bioavailable T tertiles
0 and 0.4 nmol/liter 5 38 1 (ref) 1 (ref)
0.4 and 0.8 nmol/liter 13 43 2.1 (0.6; 7.3) 1.8 (0.4; 8.2)
0.8 and 2.9 nmol/liter 14 48 2.3 (0.7; 7.8)
P trend  0.21
1.0 (0.2; 5.1)
P trend  0.84
T, Testosterone; ref, reference range category (lowest tertile of endogenous androgen).
a No. of women with severe aortic atherosclerosis compared with number of women without aortic atherosclerosis.
b RR as retrieved from logistic regression analysis, adjusted for age.
c RR as retrieved from logistic regression analysis, adjusted for age, BMI, systolic blood pressure, cholesterol level, HDL cholesterol level,
diabetes mellitus (yes/no), smoking (ever/never), alcohol intake (4 categories), time since menopause, and ever-use of hormone replacement
therapy (yes/no).
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mation of aortic atherosclerosis was available. Progression of
aortic atherosclerosis during a follow-up period of 6.5 yr
(sd 0.5 yr) was observed in 76% of men and 73% of women.
In Fig. 1, the age-adjusted odds ratios for progression of
aortic atherosclerosis according to subsequent tertiles of lev-
els of androgens are shown. Men in the second and third
tertile of levels of total and bioavailable testosterone were
protected against progression of aortic atherosclerosis (Fig.
1A). The figure suggests a protective effect of higher levels
of DHEAS against progression of aortic atherosclerosis in
men, but the corresponding test for trend did not reach
statistical significance (P  0.35). Multivariate adjustment
did not materially affect the results (data not shown). In
women, no association between tertiles of levels of andro-
gens and progression of aortic atherosclerosis was found
(Fig. 1B).
Discussion
We found an independent, inverse association between
levels of endogenous testosterone and severe aortic athero-
sclerosis and progression of aortic atherosclerosis in men. In
women, higher levels of testosterone tended to be positively
associated with severe aortic atherosclerosis and progression
of aortic atherosclerosis, although multivariate adjustment
diluted the associations. We found no clear association be-
tween levels of DHEAS and presence of severe aortic ath-
erosclerosis, either in men or in women. Our findings sug-
gested a protective effect of higher levels of DHEAS against
progression of aortic atherosclerosis in men, but the corre-
sponding test for trend did not reach statistical significance.
When interpreting our results, some methodological is-
sues should be taken into account. Due to small volumes of
plasma available, we were not able to run the assays in
duplicate, and the single sample measurement will have led
to less precise estimations of plasma levels. Furthermore, a
relatively large proportion of free testosterone measure-
ments, although random, was missing. Although these fac-
tors will have reduced the precision of our risk estimates,
they will only have led us to underestimate the strength of
the associations.
In our study sample, cardiovascular disease risk factors
tended to be more adverse in men with lower levels of
testosterone, whereas in women atherogenic changes in car-
diovascular risk factors tended to be associated with higher
levels of testosterone, which corresponds with previously
published data in men (2) and women (47). The positive
association between testosterone and cardiovascular disease
risk factors in women largely accounted for the positive
association between testosterone and aortic atherosclerosis
found in women.
Lower levels of testosterone and free testosterone have
been described in 55 male subjects with angiographically
measured coronary atherosclerosis (21). The same author
found in 60 postmenopausal women undergoing diagnostic
coronary angiography free testosterone levels to be posi-
tively associated with degree of coronary atherosclerosis
(22). Results of both described studies (21, 22) are in agree-
ment with our results. In a case-control study conducted
within the Edinburgh Artery Study among 83 subjects with
peripheral arterial disease and a comparable number of con-
trols, however, no association with testosterone was found in
either men or women (23). This discrepancy of results may
be attributable to the limited sex-specific power of this study
and the fact that peripheral arterial disease may encompass
subjects with less severe atherosclerosis than the subjects
with severe aortic atherosclerosis in our study. Contrary to
our results, a recent cross-sectional study in 101 premeno-
pausal and postmenopausal women found that women in
the highest tertiles of testosterone had significantly lower
carotid intima-media thickness independent of cardiovascu-
lar disease risk factors (24). Similar results were obtained
when analyses were restricted to the 48 postmenopausal
women (24). The apparent discrepancy between our results
and the results of studies in which no association between
endogenous testosterone levels and coronary heart disease in
men was reported (12–14) may be attributable to the fact that
we studied nonsmokers only and to the fact that the aorta
might be more vulnerable to the effects of endogenous sex
steroids than other arteries. Aortic atherosclerosis has been
found to be associated with an up to nine times increased risk
of ischemic stroke (48), indicating its importance in relation
to cardiovascular disease. Mechanisms possibly involved in
the association between aortic atherosclerosis and stroke
FIG. 1. Age-adjusted odds ratios for any progression of aortic atherosclerosis in nonsmoking men (A) and women (B). White, light gray, and
darker gray columns indicate first, second, and third tertiles, respectively, of baseline levels of endogenous androgens. T, Testesterone.
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may be pulse pressure or emboli being released from ath-
erosclerotic lesions in the aortic arch.
The mechanisms of the beneficial effect of testosterone on
atherosclerosis in males are largely unknown (49). It has been
suggested that testosterone may affect atherosclerosis
through modulation of classical cardiovascular disease risk
factors (49). The fact that multivariate adjustment did not
influence the association between testosterone and athero-
sclerosis in men in our study sample does not support this
hypothesis. Negative associations between testosterone and
the hemostatic risk factors plasminogen activator inhibitor I
(21, 50), fibrinogen (21, 50), and factor VII (51) have been
reported in men, indicating that testosterone may affect
atherogenesis through a modulation of these factors. As sug-
gested by recent animal experiments, direct beneficial effects
of testosterone on plaque development, probably mediated
by the vascular androgen receptor, may be involved (52).
Another explanation for our results that should be consid-
ered, however, is the hypothesis that higher levels of testos-
terone do not protect against atherosclerosis in men, but are
merely a marker of good health (4).
DHEAS is the most abundantly produced adrenal steroid.
It is considered to be a weak androgen, mainly contributing
to androgenicity by its peripheral conversion to the more
potent androgens testosterone and dihydrotestosterone. It
has been suggested that DHEAS exerts antiatherogenic ef-
fects (53). Nested case-control studies conducted within large
cohort studies failed to find an association between levels of
DHEAS and the onset of cardiovascular disease in men (16,
17). Results from a prospective cohort study showed that
high levels of DHEAS decreased the risk of fatal heart disease
in middle-aged men, whereas in women DHEAS offered no
protection (18). Similar sex differences were reported with
regard to coronary atherosclerosis measured by angiography
(19). In both men and women, a negative correlation between
levels of DHEAS and pulse wave velocity of the aorta, an
indicator of atherosclerosis, was found (20), and in women
a negative association between levels of DHEAS and carotid
intimal-medial thickness was described (24). Within the pro-
spective population-based Bruneck Study, however, DHEAS
was not found to be associated with development and pro-
gression of carotid atherosclerosis among 867 subjects during
5 yr of follow-up (25). Although we found no clear associ-
ation between levels of DHEAS and presence of severe aortic
atherosclerosis, our findings suggested a protective effect of
higher levels of DHEAS against progression of aortic ath-
erosclerosis in men. The corresponding test for trend, how-
ever, did not reach statistical significance. We cannot exclude
the possibility that the lack of a significant finding in our
study is due to limited sample size. The inconsistency of
results on the association between DHEAS and cardiovas-
cular disease indicate that further studies should try to elu-
cidate this issue, particularly given the high frequency of
DHEA as a treatment for aging.
In recent years, testosterone replacement strategies have
been developed for men (5), and new preparations devel-
oped specifically for women are becoming available (8).
Many of their aspects, however, remain controversial, and
increasing blood hormone levels to those found in 30- to
50-year-old individuals has not yet been uniformly proven to
be safe and of benefit (4). We have to be careful to extrapolate
our results regarding the association between endogenous
testosterone levels and aortic atherosclerosis to potential ef-
fects of therapeutic application of androgens. Dose, duration,
the identification of elderly who might benefit most, and
possible effects on the process of atherosclerosis of testos-
terone suppletion remain subjects for study (4).
In conclusion, we found an independent inverse associa-
tion between levels of testosterone and severe aortic athero-
sclerosis in men. In women, higher levels of testosterone
tended to be positively associated with severe aortic athero-
sclerosis, which was largely accounted for by more adverse
cardiovascular disease risk factors. Whether treatment with
testosterone may protect against atherogenesis in men re-
mains to be studied.
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